BioInvent International AB · OMXSTO:BINV
BioInvent International AB — Q3 2021 Earnings Presentation
11 slides from BioInvent International AB's earnings presentation, Oct 28, 2021
Slide 1: Interim report January – September 2021
Interim report January – September 2021 October 28, 2021 Martin Welschof, CEO 1 │
Slide 2: Forward-looking statement
FORWARD-LOOKING STATEMENT This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in BioInvent International AB (“BioInvent”). Neither shall the presentation or any
Slide 3: Summary interim report January – September 2021
SUMMARY INTERIM REPORT JANUARY – SEPTEMBER 2021 • 2nd clinical trial and supply agreement with Merck for BI-1808/pembrolizumab combo in Phase 2 • BI-1206/rituximab Phase 1 in NHL to be showcased at ASH (American Society of Hematology) Dec 11-14, 2021 • Early data mid-December 2021 for BI-1206/pembro
Slide 4: 2021 - Strong pipeline with multiple value drivers
2021 - STRONG PIPELINE WITH MULTIPLE VALUE DRIVERS 4 │
Slide 5: BI-1206 in combination with rituximab: open label Phase 1/2a study
BI-1206 IN COMBINATION WITH RITUXIMAB: Ongoing phase OPEN LABEL PHASE 1/2a STUDY STUDY OVERVIEW Part A Part B H1 2022E DEC 2021 BI-1206 + RTX1 (ASH, KOL event) BI-1206 + RTX1 3+3 dose escalation Expansion phase 2a Patients with: (n=9-12) PHASE 1 (n=12) relapsed or refractory iNHL 4 weekly doses foll
Slide 6: BI-1206 in combination with pembrolizumab: Phase 1/2a study with Merck
Ongoing phase BI-1206 IN COMBINATION WITH PEMBROLIZUMAB (SOLID TUMORS): PHASE 1/2a STUDY WITH MERCK STUDY OVERVIEW Part A Part B DEC 2021 (KOL event) “If successful, the potential addressable Patients with: BI-1206 + pembrolizumab EARLY BI-1206 + pembrolizumab market could be solid tumors relapsed (
Slide 7: BI-1808 (anti-TNFR2): clinical study design
Ongoing phase BI-1808 (ANTI-TNFR2): PHASE 1 ONGOING CLINICAL STUDY DESIGN Phase 1: All Cancer Types Phase 2a: Tissue-specific cohorts - 12 patients each DOSE ESCALATION – PART A BI-1808 at RP2D - Single agent BI-1808 administered at ascending doses – Single agent BI-1808 single agent Recommended Pha
Slide 8: BT-001: ongoing Phase 1/2a dose-escalation study
BT-001 (VVcopTK-RR-,ANTI-CTLA-4, GM-CSF): ONGOING PHASE 1/2A OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY PHASE 1 - PART A & B PHASE 2A SEVERAL COHORTS, DIFFERENT TUMOR TYPES UP TO 42 PATIENTS UP TO 12 PATIENTS PART B: BT-001 intratumoral administration BT-001 intratumorally in PART A: in combinat
Slide 9: Financial overview
FINANCIAL OVERVIEW SEK million Q3 2021 Q3 2020 Jan.-Sep. 2021 Jan.-Sep. 2020 Net sales 3,0 16,3 14,5 48,6 • Net sales January - September 2021 include: Operating costs • Revenues from production of antibodies for clinical studies. Research and development -57,6 -41,3 -187,9 -131,3 Sales and administ
Slide 10: What to look out for 2021
WHAT TO LOOK OUT FOR 2021 • BI-1206/rituximab in NHL – Phase 1 update at ASH Annual meeting Dec 11-14, 2021 • BI-1206/pembrolizumab in solid tumors – Early Phase 1 data Mid-Dec 2021 • BI-1206 BioInvent KOL event Mid-Dec 2021 • BI-1206 China IND Q4 2021E • BI-1607 CTA submission End of year 2021E Oct
Slide 11: www.bioinvent.com
www.bioinvent.com Follow us on LinkedIn & Twitter 11 │
BioInvent International — Q3 2021 Earnings Presentation on 6ix